Literature DB >> 12919186

Identification of a novel splice-site mutation in the CYP1A2 gene.

Delphine Allorge1, Dany Chevalier, Jean-Marc Lo-Guidice, Christelle Cauffiez, Françoise Suard, Pierre Baumann, Chin B Eap, Franck Broly.   

Abstract

AIMS: To identify the molecular basis for a low CYP1A2 metabolic status, as determined by a caffeine phenotyping test, in a 71-year-old, nonsmoking, Caucasian woman who presented with very high clozapine concentrations despite being administered a standard dose of the drug.
METHODS: The nucleotide sequence of the 7 exons, exon-intron boundaries and 5'-flanking region of the CYP1A2 gene was analysed by direct sequencing.
RESULTS: Only one heterozygous point mutation was identified in the donor splice site of intron 6 (3534G > A) of CYP1A2. This mutation could cause abnormal RNA splicing and therefore lead to a truncated nonfunctional enzyme. No other carrier of this mutation was identified in a population of 100 unrelated healthy Caucasians.
CONCLUSIONS: This is the first report of a splice-site mutation affecting the CYP1A2 gene. This polymorphism is a likely explanation for the low CYP1A2 activity associated with high clozapine concentrations in this patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919186      PMCID: PMC1884342          DOI: 10.1046/j.1365-2125.2003.01858.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population.

Authors:  D Chevalier; C Cauffiez; D Allorge; J M Lo-Guidice; M Lhermitte; J J Lafitte; F Broly
Journal:  Hum Mutat       Date:  2001-04       Impact factor: 4.878

2.  Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation.

Authors:  J Corchero; S Pimprale; S Kimura; F J Gonzalez
Journal:  Pharmacogenetics       Date:  2001-02

3.  Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.

Authors:  X M Han; D S Ou-Yang; P X Lu; C H Jiang; Y Shu; X P Chen; Z R Tan; H H Zhou
Journal:  Pharmacogenetics       Date:  2001-07

4.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences.

Authors:  M Krawczak; J Reiss; D N Cooper
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

5.  Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection.

Authors:  U Bondesson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.

Authors:  P J Perry; D D Miller; S V Arndt; R J Cadoret
Journal:  Am J Psychiatry       Date:  1991-02       Impact factor: 18.112

7.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

Authors:  U Fuhr; K L Rost
Journal:  Pharmacogenetics       Date:  1994-06

Review 8.  Human cytochrome P4501A2.

Authors:  M T Landi; R Sinha; N P Lang; F F Kadlubar
Journal:  IARC Sci Publ       Date:  1999

9.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

Authors:  M A Butler; N P Lang; J F Young; N E Caporaso; P Vineis; R B Hayes; C H Teitel; J P Massengill; M F Lawsen; F F Kadlubar
Journal:  Pharmacogenetics       Date:  1992-06

10.  Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population.

Authors:  M Chida; T Yokoi; T Fukui; M Kinoshita; J Yokota; T Kamataki
Journal:  Jpn J Cancer Res       Date:  1999-09
View more
  9 in total

1.  N-Acetyl-2-Aminofluorene (AAF) Processing in Adult Rat Hepatocytes in Primary Culture Occurs by High-Affinity Low-Velocity and Low-Affinity High-Velocity AAF Metabolite-Forming Systems.

Authors:  Katherine S Koch; Tom Moran; W Thomas Shier; Hyam L Leffert
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

Review 2.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

Review 5.  Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Authors:  Carsten Skarke; Anja Kirchhof; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

Review 6.  The Impact of CYP1A2 and CYP2E1 Genes Polymorphism on Theophylline Response.

Authors:  Em Sutrisna
Journal:  J Clin Diagn Res       Date:  2016-11-01

7.  Intronic polymorphisms of cytochromes P450.

Authors:  Magnus Ingelman-Sundberg; Sarah C Sim
Journal:  Hum Genomics       Date:  2010-08       Impact factor: 4.639

8.  Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Authors:  Kathrin Klein; Stefan Winter; Miia Turpeinen; Matthias Schwab; Ulrich M Zanger
Journal:  Front Pharmacol       Date:  2010-11-02       Impact factor: 5.810

Review 9.  Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.

Authors:  Chin B Eap
Journal:  Dialogues Clin Neurosci       Date:  2016-09       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.